VCAR-33(National Cancer Institute)

Next trem-cel clinical data update expected by year-end 2023 VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation Secured non-exclusive license to Cas9 gene-edited HSCs CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2023, and provided a business update. “We are pleased with the progress we have made during the quarter. The recent clearance of our IND for VCAR33ALLO represents a significant step forward in our vision of creating a Treatment System for acute myeloid leukemia which may enable more potent and durable responses in the post-transplant setting without on-target toxicity,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We also look forward to sharing further engraftment and Mylotarg hematologic protection data from our VBP101 clinical study by year-end.” Corporate Updates Trem-cel clinical trial (VBP101) continues to actively enroll patients; next data update expected by year-end 2023 Clinical data presented at the European Hematology Association 2023 meeting by Dr. Guenther Koehne, a clinical investigator for the VBP101 study, showed primary neutrophil engraftment in the first five patients treated and demonstrated consistent manufacturing of trem-cel with high CD33 editing efficiency. The Company plans to provide its next VBP101 clinical update by year-end 2023. The data set is expected to include engraftment data for additional patients receiving a trem-cel transplant and further Mylotarg™ hematologic protection data. Following a planned safety review of initial patients receiving trem-cel, the enrollment stagger requiring engraftment prior to transplanting subsequent patients was removed and is expected to increase the pace of enrollment. Trem-cel is a genome-edited allogeneic hematopoietic cell transplant (HCT) that is lacking the CD33 protein. It is designed to replace standard of care transplants for patients suffering from AML and potentially other blood cancers. Trem-cel has the potential to enable powerful targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts. VCAR33ALLO IND cleared by the U.S. Food & Drug Administration (FDA) The U.S. FDA has cleared the Company’s Investigational New Drug (IND) application for VCAR33ALLO, a T-cell therapy derived from allogeneic healthy donors using a chimeric antigen receptor (CAR) specifically binding to CD33. The Phase 1/2 VBP301 clinical trial will enroll patients who have relapsed following allogeneic stem cell transplant, which uses lymphoid cells harvested from the original donor as starting material for the drug product. Many of the planned clinical trial sites for VBP301 overlap with VBP101, which should optimize clinical trial site initiation. The protocol allows for patients who have received a trem-cel transplant on the VBP101 study to enroll onto VBP301 and receive VCAR33ALLO. This may provide valuable early insights into the potential of the Company’s Treatment System combining trem-cel and VCAR33ALLO to enable a more potent therapy and durable responses post-transplant. In-house clinical manufacturing of VCAR33ALLO ready to be initiated; First engineering runs in preparation for Trem-cel tech transfer completed The Company recently completed Current Good Manufacturing Practices (cGMP) qualification activities at its new in-house manufacturing facility. The site can now initiate clinical manufacturing of VCAR33ALLO for the VBP301 clinical trial. The first engineering runs required in preparation for tech transfer of trem-cel to Vor Bio’s in-house facility have been completed. The Company is on-track to commence in-house trem-cel manufacturing in 2023 and will continue to leverage a third-party to provide manufacturing redundancy. Secured worldwide non-exclusive license to Cas9 gene-edited HSCs from Editas Medicine, Inc. The company secured a worldwide non-exclusive license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The license provides access to key intellectual property for the continued development and commercialization of edited HSCs including trem-cel (VOR33), with the option to elect additional product candidate targets within the next five years. Upcoming Milestones VBP101 clinical data update including engraftment data for additional patients and further Mylotarg hematologic protection expected by year-end 2023 In-house manufacturing of trem-cel operational by year-end 2023 Second Quarter 2023 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $186.9 million as of June 30, 2023, which is projected to fund operations into the first quarter of 2025. Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2023 were $23.9 million, compared to $15.3 million for the second quarter of 2022. The increase in R&D expenses was primarily due to an increase in clinical, manufacturing and consulting expenses of $4.7 million as a result of the ongoing trem-cel clinical trial and the development of our VCAR33 programs, an increase in personnel expenses of $2.5 million, and an increase in facility costs from our laboratory and cGMP manufacturing facility expansion of $1.4 million. General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2023 were $8.3 million, compared to $6.5 million for the second quarter of 2022. The increase in G&A expense was primarily due to an increase in personnel costs of $1.4 million, including an increase in stock-based compensation expense of $1.0 million, and an increase in facilities and other expenses of $0.4 million. Net Loss: Net loss for the second quarter of 2023 was $30.0 million, compared to $21.7 million for the second quarter of 2022. Condensed Consolidated Balance Sheet Data (Unaudited) (in thousands) June 30, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 186,902 $ 230,245 Total assets 250,986 299,366 Total liabilities 46,536 48,759 Total stockholders' equity 204,450 250,607 Condensed Consolidated Statement of Operations (Unaudited) (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 23,897 $ 15,333 $ 45,812 $ 30,613 General and administrative 8,277 6,459 16,784 13,979 Total operating expenses $ 32,174 - $ 21,792 - $ 62,596 - $ 44,592 Loss from operations $ (32,174 ) $ (21,792 ) $ (62,596 ) $ (44,592 ) Other income: Interest income 2,195 133 4,184 196 Total other income 2,195 133 4,184 196 Net loss $ (29,979 ) $ (21,659 ) $ (58,412 ) $ (44,396 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.45 ) $ (0.58 ) $ (0.88 ) $ (1.19 ) Weighted-average common shares outstanding, basic and diluted 67,033,150 37,437,063 66,651,547 37,365,647 About Vor Bio Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, the timing and pace of patient enrollment in clinical trials and the availability of data therefrom, the success and timing of manufacturing clinical supply for its product candidates at its in-house manufacturing facility, the potential of overlapping clinical trial sites for VBP301 and VBP101 to optimize clinical trial site initiation, its intentions to use VCAR33ALLO in combination with trem-cel as a Treatment System and the potential benefits of such a Treatment System, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts, its potential upcoming milestones, and its cash runway and expected capital requirements. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the success of Vor Bio’s in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Contact: Investors & Media Sarah Spencer +1 857-242-6076 sspencer@vorbio.com

VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2023, and provided a business update. “We are pleased with the progress we made during the quarter. Our focus continues to be on actively enrolling and treating additional patients in our VBP101 study and submission of the VCAR33ALLO IND, which is on-track for the first half of 2023,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We look forward to sharing additional data from VBP101 at EHA in June, initiating enrollment in VBP301, and treating our first patient with VCAR33ALLO once the IND clears.” Corporate Updates Trem-cel clinical trial (VBP101) continues to actively enroll patients; next data update expected at EHA 2023 The company plans to provide further clinical updates on patients treated in the VBP101 study at the EHA2023 Congress, June 9-11, 2023, in Frankfurt, Germany, presented by Dr. Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida.The study continues to see strong investigator enthusiasm with robust enrollment.Additional trem-cel engraftment and hematologic protection data updates are expected by year-end 2023. Trem-cel is a genome-edited allogeneic hematopoietic stem cell transplant (HSCT) that is lacking the CD33 protein. It is designed to replace standard of care transplants for patients suffering from acute myeloid leukemia (AML) and potentially other blood cancers. Trem-cel has the potential to enable powerful targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts. VCAR33ALLO IND on-track for 1H 2023 submission to U.S. Food & Drug Administration (FDA) VCAR33ALLO is planned to be studied in the VBP301 clinical trial, which will focus on patients who have relapsed following allogeneic stem cell transplant where T cells harvested from the original donor are used as starting material for the drug product.The majority of the planned clinical trial sites for VBP301 overlap with VBP101, which should optimize clinical trial site initiation and enrollment. VCAR33ALLO is a T-cell therapy derived from allogeneic healthy donors using a chimeric antigen receptor (CAR) specifically binding to CD33. cGMP qualification of in-house clinical manufacturing facility nearly complete Current Good Manufacturing Practices (cGMP) qualification activities at the Company’s new in-house manufacturing facility have nearly completed, and the Company is ready to initiate clinical manufacturing of VCAR33ALLO upon IND clearance. The Company plans to commence trem-cel production at the in-house facility in 2023. Upcoming Milestones VBP101 data update at EHA in June 2023VCAR33ALLO IND submission expected in 1H 2023Additional trem-cel engraftment and hematologic protection data updates expected by year-end 2023In-house manufacturing of trem-cel operational by year-end 2023 First Quarter 2023 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $210.2 million as of March 31, 2023, which is projected to fund operations into the first quarter of 2025. Research & Development (R&D) Expenses: R&D expenses for the first quarter of 2023 were $21.9 million, compared to $15.3 million for the first quarter of 2022. The increase in R&D expenses was primarily due to an increase in clinical, manufacturing and consulting expenses as a result of the ongoing trem-cel clinical trial and the development of the VCAR33 program, an increase in personnel expenses, and an increase in facility costs from the Company’s laboratory and cGMP manufacturing facility expansion. General & Administrative (G&A) Expenses: G&A expenses for the first quarter of 2023 were $8.5 million, compared to $7.5 million for the first quarter of 2022. The increase in G&A expense was primarily due to increased personnel expenses, including an increase in stock-based compensation expense, and an increase in professional fees. Net Loss: Net loss for the first quarter of 2023 was $28.4 million, compared to $22.7 million for the first quarter of 2022. Condensed Consolidated Balance Sheet Data (Unaudited)(in thousands) March 31, December 31, 2023 2022 Cash, cash equivalents and marketable securities$210,200 $230,245 Total assets 277,533 299,366 Total liabilities 47,318 48,759 Total stockholders’ equity 230,215 250,607 Condensed Consolidated Statement of Operations (Unaudited)(in thousands, except share and per share data) Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $21,915 $15,280 General and administrative 8,507 7,520 Total operating expenses $30,422 $22,800 Loss from operations $(30,422) $(22,800)Other income: Interest income 1,989 63 Total other income 1,989 63 Net loss $(28,433) $(22,737) Net loss per share attributable to common stockholders, basic and diluted $(0.43) $(0.61)Weighted-average common shares outstanding, basic and diluted 66,265,703 37,293,438 About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, the timing and pace of patient enrollment in clinical trials and the availability of data therefrom, the timing of regulatory filings, the expected safety profile of its product candidates, the potential cGMP qualification of its manufacturing facility and the success and timing of manufacturing clinical supply for its product candidates, its intentions to use VCAR33ALLO in combination with trem-cel as a Treatment System, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts, its potential upcoming milestones, its intended use of proceeds from capital raising activities, and its cash runway and expected capital requirements. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the success of Vor Bio’s in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Contact:Investors & MediaSarah Spencer +1 857-242-6076sspencer@vorbio.com